Evidence map›Paper›PMID 30959814›Full record

ArticleNon-coding RNA2019

Sex Differences in Plasma MicroRNA Biomarkers of Early and Complicated Diabetes Mellitus in Israeli Arab and Jewish Patients.

Ari Meerson, Azwar Najjar, Elias Saad, Wisam Sbeit, Masad Barhoum, Nimer Assy

Open access · goldAbstract read
In one paragraph

Article in Non-coding RNA, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Circulating miR-15a and miR-222 as Potential Biomarkers of Type 2 Diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2020
    Article
  15. MicroRNA-423 may regulate diabetic vasculopathy.Clinical and experimental medicine · 2019
    Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ari MeersonMIGAL Galilee Research Institute, Kiryat Shmona 1101602, Israel. arim@migal.org.il.
Azwar NajjarDepartment of Internal Medicine A, Galilee Medical Center, Nahariya, Israel. dr_azwarnajjar@yahoo.com.
Elias SaadDepartment of Internal Medicine A, Galilee Medical Center, Nahariya, Israel. eliass@gmc.gov.il.
Wisam SbeitDepartment of Gastroenterology, Galilee Medical Center, Nahariya, Israel. wisams@gmc.gov.il.
Masad BarhoumDirector, Galilee Medical Center, Nahariya, Israel. masad.barhoum@naharia.health.gov.il.
Nimer AssyDepartment of Internal Medicine A, Galilee Medical Center, Nahariya, Israel. NimerA@gmc.gov.il.
Western Galilee Hospital · ILBar-Ilan University · ILMigal - Galilee Technology Center · IL

Funding

D-Cure and the Ministry of Health, Israel Diabetes Research GrantSeventh Framework Programme FP7-REGPOT-2012-2013-1, Agreement No 316157 ("CEREHA")
6 · The paper itself

Abstract

MicroRNAs play functional roles in the etiology of type 2 diabetes mellitus (T2DM) and complications, and extracellular microRNAs have attracted interest as potential biomarkers of these conditions. We aimed to identify a set of plasma microRNAs, which could serve as biomarkers of T2DM and complications in a mixed Israeli Arab/Jewish patient sample. Subjects included 30 healthy volunteers, 29 early-stage T2DM patients, and 29 late-stage T2DM patients with renal and/or vascular complications. RNA was isolated from plasma, and the levels of 12 candidate microRNAs were measured by quantitative reverse transcription and polymerase chain reaction (qRT-PCR). MicroRNA levels were compared between the groups and correlated to clinical measurements, followed by stepwise regression analysis and discriminant analysis. Plasma miR-486-3p and miR-423 were respectively up- and down-regulated in T2DM patients compared to healthy controls. MiR-28-3p and miR-423 were up-regulated in patients with complicated T2DM compared to early T2DM, while miR-486-3p was down-regulated. Combined, four microRNAs (miR-146a-5p, miR-16-2-3p, miR-126-5p, and miR-30d) could distinguish early from complicated T2DM with 77% accuracy and 79% sensitivity. In male patients only, the same microRNAs, with the addition of miR-423, could distinguish early from complicated T2DM with 83.3% accuracy. Furthermore, plasma microRNA levels showed significant correlations with clinical measurements, and these differed between men and women. Additionally, miR-183-5p levels differed significantly between the ethnic groups. Our study identified a panel of specific plasma microRNAs which can serve as biomarkers of T2DM and its complications and emphasizes the importance of sex differences in their clinical application.

Indexed as

biomarkersblood-bornecomplicationsdiabetes mellitusextracellularmicroRNAssex differences

Identifiers

PMID30959814
PMCPMC6631160
OpenAlexW2931511392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.